B. Spear, M. Heath-chiozzi, and J. Huff, Clinical application of pharmacogenetics, Trends in Molecular Medicine, vol.7, issue.5, pp.201-205, 2001.
DOI : 10.1016/S1471-4914(01)01986-4

M. Huang, A. Shen, J. Ding, and M. Geng, Molecularly targeted cancer therapy: some lessons from the past decade, Trends in Pharmacological Sciences, vol.35, issue.1, pp.41-50, 2014.
DOI : 10.1016/j.tips.2013.11.004

R. Luengo-fernandez, J. Leal, A. Gray, and R. Sullivan, Economic burden of cancer across the European Union: a population-based cost analysis, The Lancet Oncology, vol.14, issue.12, pp.1165-74, 2013.
DOI : 10.1016/S1470-2045(13)70442-X

A. Deyati, E. Younesi, M. Hofmann-apitius, and N. Novac, Challenges and opportunities for oncology biomarker discovery, Drug Discovery Today, vol.18, issue.13-14, pp.614-638, 2013.
DOI : 10.1016/j.drudis.2012.12.011

H. Wheeler, M. Maitland, M. Dolan, N. Cox, and M. Ratain, Cancer pharmacogenomics: strategies and challenges, Nature Reviews Genetics, vol.99, issue.1, pp.23-34, 2013.
DOI : 10.1093/jnci/djm115
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3668552/pdf

T. Hudson, W. Anderson, A. Artez, A. Barker, C. Bell et al., International network of cancer genome projects, Nature, vol.452, issue.7291, pp.993-1001, 2010.
DOI : 10.1038/nature08987
URL : https://hal.archives-ouvertes.fr/hal-00868358

H. Mcleod, Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed, Science, vol.89, issue.3, pp.1563-1569, 2013.
DOI : 10.1038/clpt.2010.279

O. Abaan, E. Polley, S. Davis, Y. Zhu, S. Bilke et al., The Exomes of the NCI-60 Panel: A Genomic Resource for Cancer Biology and Systems Pharmacology, Cancer Research, vol.73, issue.14, pp.4372-82, 2013.
DOI : 10.1158/0008-5472.CAN-12-3342

M. Garnett, E. Edelman, S. Heidorn, C. Greenman, A. Dastur et al., Systematic identification of genomic markers of drug sensitivity in cancer cells, Nature, vol.58, issue.7391, pp.570-575, 2012.
DOI : 10.1101/gr.1239303

J. Barretina, G. Caponigro, N. Stransky, K. Venkatesan, A. Margolin et al., The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, vol.53, issue.7391, pp.307-603, 2012.
DOI : 10.1002/pbc.20697

J. Weinstein, Cell lines battle cancer, Nature, vol.464, issue.7391, pp.544-549, 2012.
DOI : 10.1038/nature08987

M. Menden, F. Iorio, M. Garnett, U. Mcdermott, C. Benes et al., Machine Learning Prediction of Cancer Cell Sensitivity to Drugs Based on Genomic and Chemical Properties, PLoS ONE, vol.2, issue.3, p.61318, 2013.
DOI : 10.1371/journal.pone.0061318.s007

M. Ammad-ud-din, E. Georgii, M. Gönen, T. Laitinen, O. Kallioniemi et al., Integrative and Personalized QSAR Analysis in Cancer by Kernelized Bayesian Matrix Factorization, Journal of Chemical Information and Modeling, vol.54, issue.8, pp.2347-59, 2014.
DOI : 10.1021/ci500152b

I. Cortés-ciriano, G. Van-westen, G. Bouvier, M. Nilges, J. Overington et al., Improved large-scale prediction of growth inhibition patterns using the NCI60 cancer cell line panel, Bioinformatics, vol.14, issue.74, pp.85-95, 2016.
DOI : 10.1093/bioinformatics/btq176

G. Riddick, H. Song, S. Ahn, J. Walling, D. Borges-rivera et al., Predicting in vitro drug sensitivity using Random Forests, Bioinformatics, vol.5, issue.2, pp.220-224, 2011.
DOI : 10.1158/1535-7163.MCT-06-0640
URL : https://academic.oup.com/bioinformatics/article-pdf/27/2/220/16899420/btq628.pdf

P. Geeleher, N. Cox, and R. Huang, Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines, Genome Biology, vol.15, issue.3, p.47, 2014.
DOI : 10.1002/gepi.21750

A. Lee, K. Shedden, G. Rosania, and G. Crippen, Data Mining the NCI60 to Predict Generalized Cytotoxicity, Journal of Chemical Information and Modeling, vol.48, issue.7, pp.1379-88, 2008.
DOI : 10.1021/ci800097k
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2561991/pdf

R. Kumar, K. Chaudhary, D. Singla, A. Gautam, and G. Raghava, Designing of promiscuous inhibitors against pancreatic cancer cell lines, Scientific Reports, vol.12, issue.1, p.4668, 2014.
DOI : 10.1038/nrd4128

S. Holbeck, J. Collins, and J. Doroshow, Analysis of Food and Drug Administration-Approved Anticancer Agents in the NCI60 Panel of Human Tumor Cell Lines, Molecular Cancer Therapeutics, vol.9, issue.5, pp.1451-60, 2010.
DOI : 10.1158/1535-7163.MCT-10-0106

M. Füllbeck, M. Dunkel, J. Hossbach, P. Daniel, and R. Preissner, Cellular Fingerprints: A Novel Approach Using Large-Scale Cancer Cell Line Data for the Identification of Potential Anticancer Agents, Chemical Biology & Drug Design, vol.30, issue.50, pp.439-487, 2009.
DOI : 10.1021/ci049920h

T. Cheng, Y. Wang, and S. Bryant, Investigating the correlations among the chemical structures, bioactivity profiles and molecular targets of small molecules, Bioinformatics, vol.302, issue.22, pp.2881-2889, 2010.
DOI : 10.1126/science.1091867

Y. Benjamini and Y. Hochberg, Controlling the false discovery rate: a practical and powerful approach to multiple testing, J R Stat Soc Ser B, vol.57, pp.289-300, 1995.

J. Malley, A. Dasgupta, and J. Moore, The limits of p-values for biological data mining, BioData Mining, vol.1, issue.1, p.10, 2013.
DOI : 10.1097/00001648-199001000-00010

H. Motulsky, Common Misconceptions about Data Analysis and Statistics, Journal of Pharmacology and Experimental Therapeutics, vol.351, issue.1, pp.200-205, 2014.
DOI : 10.1124/jpet.114.219170
URL : http://onlinelibrary.wiley.com/doi/10.1111/bph.12884/pdf

R. Nuzzo, Scientific method: Statistical errors, Nature, vol.506, issue.7487, pp.150-152, 2014.
DOI : 10.1038/506150a
URL : http://www.nature.com:80/polopoly_fs/1.14700!/menu/main/topColumns/topLeftColumn/pdf/506150a.pdf

R. Hoekstra, H. Kiers, and A. Johnson, Are Assumptions of Well-Known Statistical Techniques Checked, and Why (Not)?, Frontiers in Psychology, vol.3, p.137, 2012.
DOI : 10.3389/fpsyg.2012.00137
URL : http://journal.frontiersin.org/article/10.3389/fpsyg.2012.00137/pdf

. Wiley, Nonparametric Tests for Complete Data -Vilijandas Bagdonavièus, Julius Kruopis, Mikhail Nikulin, 2018.

B. Matthews, Comparison of the predicted and observed secondary structure of T4 phage lysozyme, Biochimica et Biophysica Acta (BBA) - Protein Structure, vol.405, issue.2, pp.442-51, 1975.
DOI : 10.1016/0005-2795(75)90109-9

D. Sheskin, Handbook of parametric and nonparametric statistical procedures, 2007.
DOI : 10.1201/9781420036268

O. Chedzoy, Phi-coefficient, Encyclopedia of Statistical Sciences, 2006.
DOI : 10.1002/0471667196.ess1960

G. Papadatos, G. Van-westen, S. Croset, R. Santos, S. Trubian et al., A document classifier for medicinal chemistry publications trained on the ChEMBL corpus, Journal of Cheminformatics, vol.100, issue.1, p.40, 2014.
DOI : 10.3163/1536-5050.100.2.007

M. Vihinen, How to evaluate performance of prediction methods? Measures and their interpretation in variation effect analysis, BMC Genomics, vol.13, issue.Suppl 4, p.2, 2012.
DOI : 10.1186/1471-2164-13-S4-S2

S. Smusz, R. Kurczab, and A. Bojarski, The influence of the inactives subset generation on the performance of machine learning methods, Journal of Cheminformatics, vol.5, issue.1, p.17, 2013.
DOI : 10.1145/1656274.1656278

F. Klepsch, P. Vasanthanathan, and G. Ecker, Ligand and Structure-Based Classification Models for Prediction of P-Glycoprotein Inhibitors, Journal of Chemical Information and Modeling, vol.54, issue.1, pp.218-247, 2014.
DOI : 10.1021/ci400289j

A. Kolchinsky, A. Abi-haidar, J. Kaur, A. Hamed, and L. Rocha, Classification of Protein-Protein Interaction Full-Text Documents Using Text and Citation Network Features, IEEE/ACM Transactions on Computational Biology and Bioinformatics, vol.7, issue.3, pp.400-411, 2010.
DOI : 10.1109/TCBB.2010.55

S. Poil, W. De-haan, W. Van-der-flier, H. Mansvelder, P. Scheltens et al., Integrative EEG biomarkers predict progression to Alzheimer's disease at the MCI stage, Frontiers in Aging Neuroscience, vol.5, p.58, 2013.
DOI : 10.3389/fnagi.2013.00058

J. Lever, M. Krzywinski, and N. Altman, Classification evaluation, Nature Methods, vol.13, issue.8, pp.603-607, 2016.
DOI : 10.1038/nmeth.3904

A. De-gramont, S. Watson, L. Ellis, J. Rodón, J. Tabernero et al., Pragmatic issues in biomarker evaluation for targeted therapies in cancer, Nature Reviews Clinical Oncology, vol.31, issue.4, pp.197-212, 2014.
DOI : 10.1007/s11095-005-2495-9

B. Tran, J. Dancey, S. Kamel-reid, J. Mcpherson, P. Bedard et al., Cancer Genomics: Technology, Discovery, and Translation, Journal of Clinical Oncology, vol.30, issue.6, pp.647-60, 2012.
DOI : 10.1200/JCO.2011.39.2316

J. Ahmed, T. Meinel, M. Dunkel, M. Murgueitio, R. Adams et al., CancerResource: a comprehensive database of cancer-relevant proteins and compound interactions supported by experimental knowledge, Nucleic Acids Research, vol.44, issue.suppl_1, pp.960-967, 2011.
DOI : 10.1007/978-1-4419-1274-9_8

P. Boutros, A. Margolin, J. Stuart, A. Califano, and G. Stolovitzky, Toward better benchmarking: challenge-based methods assessment in cancer genomics, Genome Biology, vol.17, issue.9
DOI : 10.1373/clinchem.2009.126698
URL : https://genomebiology.biomedcentral.com/track/pdf/10.1186/s13059-014-0462-7?site=genomebiology.biomedcentral.com

B. Haibe-kains, N. El-hachem, N. Birkbak, A. Jin, A. Beck et al., Inconsistency in large pharmacogenomic studies, Nature, vol.85, issue.7480, pp.389-93, 2013.
DOI : 10.1038/75556
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237165/pdf

J. Weinstein and P. Lorenzi, Discrepancies in drug sensitivity, Nature, vol.276, issue.7480, pp.381-384, 2013.
DOI : 10.1038/ng.2764

M. Patel, M. Halling-brown, J. Tym, P. Workman, and B. Lazikani, Objective assessment of cancer genes for drug discovery, Nature Reviews Drug Discovery, vol.8, issue.1, pp.35-50, 2013.
DOI : 10.1007/s10969-007-9027-2

T. Pemovska, M. Kontro, B. Yadav, H. Edgren, S. Eldfors et al., Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia, Cancer Discovery, vol.3, issue.12, pp.1416-1445, 2013.
DOI : 10.1158/2159-8290.CD-13-0350

H. Kamiyama, S. Rauenzahn, J. Shim, C. Karikari, G. Feldmann et al., Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice, Clinical Cancer Research, vol.19, issue.5, pp.1139-1185, 2013.
DOI : 10.1158/1078-0432.CCR-12-2127
URL : http://clincancerres.aacrjournals.org/content/clincanres/19/5/1139.full.pdf

S. Williams, W. Anderson, M. Santaguida, and S. Dylla, Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century, Laboratory Investigation, vol.50, issue.9, pp.970-82, 2013.
DOI : 10.1016/j.lungcan.2011.10.017

H. Gao, J. Korn, S. Ferretti, J. Monahan, Y. Wang et al., High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response, Nature Medicine, vol.9, issue.11, pp.1318-1343, 2015.
DOI : 10.1038/nbt.1549

R. Simon and S. Roychowdhury, Implementing personalized cancer genomics in clinical trials, Nature Reviews Drug Discovery, vol.7, issue.5, pp.358-69, 2013.
DOI : 10.1371/journal.pone.0037029

B. Majumder, U. Baraneedharan, S. Thiyagarajan, P. Radhakrishnan, H. Narasimhan et al., Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity, Nature Communications, vol.19, issue.80, p.6169, 2015.
DOI : 10.1162/neco.2007.19.3.792
URL : http://www.nature.com/articles/ncomms7169.pdf

C. Klijn, S. Durinck, E. Stawiski, P. Haverty, Z. Jiang et al., A comprehensive transcriptional portrait of human cancer cell lines, Nature Biotechnology, vol.88, issue.3, pp.306-318, 2014.
DOI : 10.1016/j.ajhg.2011.03.004

M. Makridakis and A. Vlahou, Secretome proteomics for discovery of cancer biomarkers, Journal of Proteomics, vol.73, issue.12, pp.2291-305, 2010.
DOI : 10.1016/j.jprot.2010.07.001

J. Costello, L. Heiser, E. Georgii, M. Gönen, M. Menden et al., A community effort to assess and improve drug sensitivity prediction algorithms, Nature Biotechnology, vol.33, issue.12, pp.1202-1214, 2014.
DOI : 10.1093/jnci/83.11.757
URL : https://hal.archives-ouvertes.fr/hal-01101874

N. Potter, L. Ermini, E. Papaemmanuil, G. Cazzaniga, G. Vijayaraghavan et al., Single-cell mutational profiling and clonal phylogeny in cancer, Genome Research, vol.23, issue.12, pp.2115-2140, 2013.
DOI : 10.1101/gr.159913.113
URL : http://genome.cshlp.org/content/23/12/2115.full.pdf

B. Al-lazikani, U. Banerji, and P. Workman, Combinatorial drug therapy for cancer in the post-genomic era, Nature Biotechnology, vol.39, issue.7, pp.679-92, 2012.
DOI : 10.1093/nar/gkq1116